On 2026年4月23日, the U.S. FDA released the "Medical Sensor Cybersecurity Guidance v2.1", making it clear that mandatory cybersecurity requirements will be imposed on medical sensors with wireless communication functions starting from 2026年6月1日. This policy directly affects Chinese medical sensor exporters targeting the U.S. market, ODM/OEM manufacturers, and supply chain service providers, as it is directly related to customs compliance and product market access qualifications.

Event Overview

On 2026年4月23日, the U.S. FDA officially released the "Medical Sensor Cybersecurity Guidance v2.1". The guidance stipulates that all medical sensors equipped with wireless communication capabilities such as Bluetooth, Wi-Fi, or LoRaWAN must meet three technical requirements starting from 2026年6月1日——support AES-256 encrypted transmission, implement OTA firmware signature verification, and provide remote secure audit log export functionality. It also makes clear that if Chinese exporters fail to complete both FCC ID certification and FDA UDI registration, and fail to pass third-party penetration testing, they will face the risk of customs clearance delays or rejection of entire shipments at U.S. ports.

Which Segments Will Be Affected

Direct Trading Companies

As they bear responsibility for export declaration and compliance, if their products do not have the corresponding FCC ID number and FDA UDI code, they will be unable to complete the U.S. import customs declaration form (CBP Form 7501). The impact is reflected in longer customs clearance times, increased port detention charges, and interruption of customer order fulfillment.

Processing and Manufacturing Enterprises（including ODM/OEM）

They need to integrate AES-256 encryption and decryption modules, secure boot mechanisms, and log storage interfaces during the hardware design stage; at the software level, the OTA upgrade process must be restructured to support firmware signature verification. Companies that fail to adapt in advance may face production line rework, rising BOM costs, and delivery delays.

Supply Chain Service Companies（including testing and certification institutions, compliance consulting service providers）

The guidance adds penetration testing as a mandatory prerequisite, which will drive increased demand for dedicated cybersecurity testing for medical sensors. Service offerings must cover dual-dimension verification of FCC radio frequency consistency + FDA cybersecurity, and existing service capabilities focused only on EMC/RF testing are no longer sufficient.

Key Points Relevant Companies or Practitioners Should Focus On and How to Respond Now

Immediately Verify the Technical Documentation of Wireless Communication Modules in Products on Sale/in Development

Confirm whether AES-256 algorithms are already supported, whether secure boot pins are reserved, and whether log storage meets the FDA-required minimum retention period (如≥30天) and export protocol (如HTTPS+TLS 1.2+).

Simultaneously Launch the Dual-Track Process for FCC ID Application and FDA UDI Registration

The FCC ID must be issued by an FCC-recognized TCB body, while the FDA UDI must be submitted through the GUDID system; neither can be registered in the name of an agent. Both must be completed in the name of the actual exporter or manufacturer, and the information must be fully consistent.

Prioritize Third-Party Penetration Testing and Retain Complete Reports

Testing must cover three categories of attack surfaces: wireless communication channels, OTA upgrade interfaces, and log export endpoints. The report must be issued by a laboratory qualified under ISO/IEC 17025, and the signing date must not be later than 2026年5月20日, so as to leave a customs clearance buffer period.

Evaluate Existing Contract Clauses Regarding Compliance Responsibility

If procurement agreements signed with overseas customers do not clearly specify the party responsible for cybersecurity compliance obligations (如 the manufacturer bearing the cost of encryption modifications), supplemental agreement negotiations need to be completed before the end of 2026年5月 to avoid breach-of-contract disputes caused by technical non-compliance after 6月.

Editorial Viewpoint / Industry Observation

From an industry perspective, this guidance update is not an isolated technical upgrade, but a landmark point where the FDA shifts cybersecurity from "recommended control" to an "access threshold". Analysis suggests that its core intention is to bring medical sensors into a regulatory intensity level equivalent to connected imaging equipment and remote monitoring systems. What deserves more attention at present is that this requirement has not yet been extended to purely wired devices, nor does it mandate compliance with UL 2900 or IEC 81001-5-1 standards, indicating that the FDA is currently focused on verifiable and enforceable foundational protection capabilities. It is more appropriately understood as the implementation push of "minimum viable compliance" (MVP Compliance), rather than the beginning of a comprehensive security system overhaul.

Conclusion

This guidance marks the entry of U.S. cybersecurity regulation for imported medical sensors into the implementation stage. Its industry significance lies not in technical complexity, but in turning three indicators—encryption capability, firmware trust mechanisms, and audit traceability—into hard market access requirements. At present, it is more appropriate to interpret this as a compliance stress test for export enterprises——whether they can complete technical adaptation and the certification closed loop within two months will become a key benchmark for measuring a company’s cross-border compliance response capability.

Source Information Note

Main source: the "Medical Sensor Cybersecurity Guidance v2.1" published on the official website of the U.S. FDA (发布日期：2026年4月23日). Ongoing observation points: whether the FDA will subsequently issue supplementary FAQ documents on details such as AES-256 key management and log format specifications.